Withaferin-A for steroid-resistant graft-versus-host disease
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a plant-based medicine, Withaferin-A, in people whose graft-versus-host disease (GVHD) after a stem cell transplant has not responded to steroid treatment. GVHD is a condition where donated immune cells attack the body; this study aims to see if Withaferin-A can help control it.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 12 years or older and had a blood cancer treated with a stem cell transplant from a related, half-matched related, or unrelated matched donor.
- Your new immune cells have started working (your neutrophil count has been at a safe level for 3 days).
- You are able to do normal daily activities with little or no help (ECOG score 0 or 1).
- Your GVHD did not get better after at least 3 days of high-dose steroids, got worse after 7 days, or you cannot reduce your steroid dose without GVHD returning or spreading to a new organ.
- You do not have an active, uncontrolled infection that makes you unstable, and you are not allergic to Withaferin-A.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a natural compound called Withaferin A (from ashwagandha) to see if it helps prevent graft-versus-host disease (GVHD) after a stem cell transplant. The goal is to reduce the risk of transplant complications.
This trial studies a type of immune-support cell therapy (mesenchymal stromal cells) compared with the best available standard treatment for acute graft-versus-host disease (aGvHD) that does not respond to steroids. It may help by calming an overactive immune reaction after a stem cell transplant.
This trial tests if a two-step course of a drug called ATG (anti-thymocyte globulin) can help prevent a serious side effect called graft-versus-host disease (GVHD) after a donor stem cell transplant. It is for people with certain blood cancers who are receiving a reduced-intensity transplant.
This trial tests whether moxibustion—a traditional Chinese medicine technique using heat from burning mugwort—can help treat acute graft-versus-host disease (a complication after bone marrow transplant) that hasn't responded to steroid drugs. If you've had a stem cell transplant and developed this condition that won't go away with standard treatment, this study may be for you.
This trial tests a combination of a steroid and a humanized antibody (called CD25 monoclonal antibody) as the first treatment for moderate to severe acute graft-versus-host disease (aGVHD) after a stem cell transplant. The goal is to see if this combination is safer and more effective than steroids alone.
This trial tests a new approach to prevent graft-versus-host disease (GVHD) after a stem cell transplant from a matched donor. It is for people aged 60 or older with a blood cancer or serious blood disorder who are getting a reduced-intensity conditioning regimen.
Hear when a new GVHD - Graft-Versus-Host Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.